AR095072A1 - Conjugados antibióticos - Google Patents
Conjugados antibióticosInfo
- Publication number
- AR095072A1 AR095072A1 ARP140100773A ARP140100773A AR095072A1 AR 095072 A1 AR095072 A1 AR 095072A1 AR P140100773 A ARP140100773 A AR P140100773A AR P140100773 A ARP140100773 A AR P140100773A AR 095072 A1 AR095072 A1 AR 095072A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibiotic conjugates
- antibiotic
- covalent bonds
- conjugates
- linker
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
- C07K7/645—Cyclosporins; Related peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Botany (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
Abstract
Reivindicación 1: Una droga híbrida que comprende por lo menos dos porciones antibióticas, o una sal farmacéutica de la misma, que se conectan vía dos enlaces covalentes con un enlazador de manera que dichos enlaces covalentes se degradan in vivo para producir los antibióticos respectivos independientemente.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361775216P | 2013-03-08 | 2013-03-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR095072A1 true AR095072A1 (es) | 2015-09-16 |
Family
ID=50382692
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP140100773A AR095072A1 (es) | 2013-03-08 | 2014-03-07 | Conjugados antibióticos |
ARP140100774A AR095073A1 (es) | 2013-03-08 | 2014-03-07 | Compuesto híbrido con una porción ciclosporina a y una porción de esteroide, uso de dicho compuesto para preparar una composición farmacéutica tópica y dicha composición |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP140100774A AR095073A1 (es) | 2013-03-08 | 2014-03-07 | Compuesto híbrido con una porción ciclosporina a y una porción de esteroide, uso de dicho compuesto para preparar una composición farmacéutica tópica y dicha composición |
Country Status (16)
Country | Link |
---|---|
US (4) | US9402913B2 (es) |
EP (2) | EP2964268A1 (es) |
JP (1) | JP2016510754A (es) |
KR (1) | KR20150125663A (es) |
CN (1) | CN105025929A (es) |
AR (2) | AR095072A1 (es) |
AU (1) | AU2014225637A1 (es) |
BR (1) | BR112015021388A2 (es) |
CA (1) | CA2899500A1 (es) |
CL (1) | CL2015002210A1 (es) |
IL (1) | IL240920A0 (es) |
PH (1) | PH12015501857A1 (es) |
RU (1) | RU2015135145A (es) |
SG (1) | SG11201507241UA (es) |
TW (2) | TW201511758A (es) |
WO (4) | WO2014138403A1 (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2015011948A (es) | 2013-03-08 | 2015-12-09 | Allergan Inc | Antibioticos conjugados directamente relacionados con farmacos esteroides. |
SG11201507241UA (en) | 2013-03-08 | 2015-10-29 | Allergan Inc | Cyclosporine a-steroid conjugates |
US11072668B2 (en) | 2017-01-03 | 2021-07-27 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing alginates as biodegradable antibacterial scaffolds and methods pertaining thereto |
CA3055474A1 (en) | 2017-03-28 | 2018-10-04 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing polyaminoglycosides as biodegradable antibacterial scaffolds and methods pertaining thereto |
US11612567B2 (en) | 2018-02-02 | 2023-03-28 | Ripple Therapeutics Corporation | Ocular inserts comprising a covalently linked steroid dimer |
JP2021515083A (ja) | 2018-03-06 | 2021-06-17 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒルThe University Of North Carolina At Chapel Hill | 生分解性の抗菌性足場としての一酸化窒素放出性シクロデキストリンおよびそれに関する方法 |
WO2019246312A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
AU2019325261A1 (en) * | 2018-08-22 | 2021-03-18 | Bacainn Biotherapeutics, Ltd. | Cyclosporine compositions and methods of use |
SG11202101517PA (en) * | 2018-08-31 | 2021-03-30 | Aerie Pharmaceuticals Inc | Isoquinoline-steroid conjugates and uses thereof |
CA3124673A1 (en) | 2018-12-28 | 2020-07-02 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing antibacterial polymers and scaffolds fabricated therefrom and methods pertaining thereto |
CA3176134A1 (en) | 2020-05-01 | 2021-11-04 | Ripple Therapeutics Corporation | Heterodimer compositions and methods for the treatment of ocular disorders |
WO2023079362A1 (en) * | 2021-11-03 | 2023-05-11 | Ripple Therapeutics Corporation | Processable compositions and use for the same |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2999102A (en) * | 1959-10-14 | 1961-09-05 | Thomae Gmbh Dr K | Bis-(steroid-21)-dicarboxylic acid esters |
US3147183A (en) * | 1962-04-16 | 1964-09-01 | Boehringer Sohn Ingelheim | Bis-(steroid-21)-dicarboxylic acid esters |
US3916002A (en) * | 1973-12-17 | 1975-10-28 | Taubert Hans Dieter | Oligomeric steroid esters, process for their production, and therapeutic compositions containing the same |
EP0194972B1 (en) | 1985-03-11 | 1992-07-29 | Sandoz Ag | Novel cyclosporins |
JPH089597B2 (ja) | 1986-01-21 | 1996-01-31 | 杏林製薬株式会社 | 選択毒性に優れた8‐アルコキシキノロンカルボン酸およびその塩並びにその製造方法 |
US4839342A (en) | 1987-09-03 | 1989-06-13 | University Of Georgia Research Foundation, Inc. | Method of increasing tear production by topical administration of cyclosporin |
EP0629292A1 (en) | 1993-01-06 | 1994-12-21 | Beckman Instruments, Inc. | Method for making a preconjugate |
US5688792A (en) | 1994-08-16 | 1997-11-18 | Pharmacia & Upjohn Company | Substituted oxazine and thiazine oxazolidinone antimicrobials |
CA2136803A1 (en) | 1993-12-22 | 1995-06-23 | Kazumi Ogata | Steroid derivatives |
AU705226B2 (en) | 1994-01-28 | 1999-05-20 | University Of Kentucky Research Foundation, The | Codrugs as a method of controlled drug delivery |
US6051576A (en) | 1994-01-28 | 2000-04-18 | University Of Kentucky Research Foundation | Means to achieve sustained release of synergistic drugs by conjugation |
US5474979A (en) | 1994-05-17 | 1995-12-12 | Allergan, Inc. | Nonirritating emulsions for sensitive tissue |
US5565568A (en) | 1995-04-06 | 1996-10-15 | Eli Lilly And Company | 2-acylaminopropanamides as tachykinin receptor antagonists |
US6350422B1 (en) | 1998-09-21 | 2002-02-26 | Phillips Petroleum Company | Sorbent compositions |
US6254860B1 (en) | 1999-04-13 | 2001-07-03 | Allergan Sales, Inc. | Ocular treatment using cyclosporin-A derivatives |
WO2001005819A1 (en) | 1999-07-15 | 2001-01-25 | Kuhnil Pharm. Co., Ltd. | Novel water soluble-cyclosporine conjugated compounds |
US20010049366A1 (en) * | 2000-02-09 | 2001-12-06 | Alcon Universal Ltd. | Topical solution formulations containing an antibiotic and a corticosteroid |
US6306842B1 (en) | 2000-06-02 | 2001-10-23 | Medinox, Inc. | Protected forms of a combination of pharmacologically active agents and uses therefor |
IL158527A0 (en) | 2001-04-26 | 2004-05-12 | Control Delivery Sys Inc | Sustained release drug delivery system containing codrugs |
WO2003031443A1 (en) | 2001-10-04 | 2003-04-17 | Morphochem Aktiengesellschaft für kombinatorische Chemie | Dual actions antibiotics comprising a oxazoldinone and a quinolone or naphthyridinone moiety |
WO2003031441A1 (en) | 2001-10-04 | 2003-04-17 | Morphochen Aktiengesellschaft Für Kombinatorische Chemie | Multiple action compounds |
AUPR879601A0 (en) * | 2001-11-09 | 2001-12-06 | Biota Scientific Management Pty Ltd | Novel chemical compounds and their use |
JP2005518354A (ja) * | 2001-11-19 | 2005-06-23 | コントロール・デリバリー・システムズ・インコーポレイテッド | コドラッグを含有する医薬組成物 |
WO2004082629A2 (en) | 2003-03-17 | 2004-09-30 | Albany Molecular Research, Inc. | Novel cyclosporins |
HRP20030324A2 (en) | 2003-04-24 | 2005-02-28 | Pliva-Istra�iva�ki institut d.o.o. | Compounds of antiinflammatory effect |
WO2004096221A1 (en) | 2003-04-30 | 2004-11-11 | Morphochem Aktiengesellschaft für kombinatorische Chemie | Use of oxazolidinone-quinoline hybrid antibiotics for the treatment of anthrax and other infections |
WO2004112838A2 (en) * | 2003-05-21 | 2004-12-29 | Control Delivery Systems, Inc. | Codrugs of diclofenac |
US20050059583A1 (en) | 2003-09-15 | 2005-03-17 | Allergan, Inc. | Methods of providing therapeutic effects using cyclosporin components |
US20060105941A1 (en) * | 2004-11-12 | 2006-05-18 | Allergan, Inc. | Mixed antibiotic codrugs |
US7288520B2 (en) | 2005-07-13 | 2007-10-30 | Allergan, Inc. | Cyclosporin compositions |
WO2008069824A2 (en) | 2006-02-27 | 2008-06-12 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for transport of molecules with enhanced release properties across biological barriers |
WO2008094507A2 (en) | 2007-01-26 | 2008-08-07 | Cellicon Biotechnologies, Inc. | Novel fusion compounds |
ITMI20080382A1 (it) | 2008-03-07 | 2009-09-08 | Ctg Pharma S R L | Composizioni farmaceutiche oculari |
BRPI0915552A2 (pt) | 2008-07-10 | 2017-06-20 | Allergan Inc | derivados de ciclosporina, seu uso e sua composição farmacêutica |
MX2008014515A (es) * | 2008-09-09 | 2010-04-29 | Allergan Inc | Suspension oftalmica para uso ocular. |
EP2413974B1 (en) * | 2009-03-31 | 2016-03-23 | Technion Research & Development Foundation Ltd. | Conjugated antimicrobial agents |
CA2763207A1 (en) | 2009-05-27 | 2010-12-02 | Allergan, Inc. | Cyclosporin derivatives for treating inflammatory diseases and conditions |
US9175042B2 (en) | 2010-10-12 | 2015-11-03 | Allergan, Inc. | Cyclosporin analogs |
RU2013119869A (ru) | 2010-10-12 | 2014-11-20 | Аллерган, Инк. | Аналоги циклоспорина |
IN2014CN02688A (es) * | 2011-09-16 | 2015-07-03 | Davidson Lopez Llc | |
WO2013181339A2 (en) | 2012-06-01 | 2013-12-05 | Allergan, Inc. | Cyclosporin a analogs |
WO2014138343A1 (en) | 2013-03-08 | 2014-09-12 | Allergan, Inc. | Antibiotic conjugates with nonsteroidal anti-inflammatory drugs |
MX2015011948A (es) | 2013-03-08 | 2015-12-09 | Allergan Inc | Antibioticos conjugados directamente relacionados con farmacos esteroides. |
SG11201507241UA (en) | 2013-03-08 | 2015-10-29 | Allergan Inc | Cyclosporine a-steroid conjugates |
MX2015011847A (es) | 2013-03-08 | 2016-01-08 | Allergan Inc | Conjugados antibioticos vinculados con farmacos esteorides. |
-
2014
- 2014-03-06 SG SG11201507241UA patent/SG11201507241UA/en unknown
- 2014-03-06 EP EP14712952.2A patent/EP2964268A1/en not_active Withdrawn
- 2014-03-06 US US14/199,432 patent/US9402913B2/en active Active
- 2014-03-06 WO PCT/US2014/021219 patent/WO2014138403A1/en active Application Filing
- 2014-03-06 US US14/199,310 patent/US20140256658A1/en not_active Abandoned
- 2014-03-06 EP EP14712954.8A patent/EP2964269A1/en not_active Withdrawn
- 2014-03-06 US US14/199,212 patent/US20140256694A1/en not_active Abandoned
- 2014-03-06 CN CN201480012214.9A patent/CN105025929A/zh active Pending
- 2014-03-06 RU RU2015135145A patent/RU2015135145A/ru not_active Application Discontinuation
- 2014-03-06 CA CA2899500A patent/CA2899500A1/en not_active Abandoned
- 2014-03-06 AU AU2014225637A patent/AU2014225637A1/en not_active Abandoned
- 2014-03-06 WO PCT/US2014/021314 patent/WO2014138437A1/en active Application Filing
- 2014-03-06 KR KR1020157024379A patent/KR20150125663A/ko not_active Application Discontinuation
- 2014-03-06 US US14/199,514 patent/US20140256696A1/en not_active Abandoned
- 2014-03-06 WO PCT/US2014/021096 patent/WO2014138359A1/en active Application Filing
- 2014-03-06 WO PCT/US2014/021283 patent/WO2014138425A1/en active Application Filing
- 2014-03-06 JP JP2015561664A patent/JP2016510754A/ja active Pending
- 2014-03-06 BR BR112015021388A patent/BR112015021388A2/pt not_active IP Right Cessation
- 2014-03-07 AR ARP140100773A patent/AR095072A1/es unknown
- 2014-03-07 AR ARP140100774A patent/AR095073A1/es unknown
- 2014-03-10 TW TW103108219A patent/TW201511758A/zh unknown
- 2014-03-10 TW TW103108198A patent/TW201511768A/zh unknown
-
2015
- 2015-08-07 CL CL2015002210A patent/CL2015002210A1/es unknown
- 2015-08-24 PH PH12015501857A patent/PH12015501857A1/en unknown
- 2015-08-30 IL IL240920A patent/IL240920A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
US20140256696A1 (en) | 2014-09-11 |
EP2964269A1 (en) | 2016-01-13 |
TW201511768A (zh) | 2015-04-01 |
US20140256651A1 (en) | 2014-09-11 |
PH12015501857A1 (en) | 2015-12-07 |
IL240920A0 (en) | 2015-10-29 |
WO2014138437A1 (en) | 2014-09-12 |
US20140256694A1 (en) | 2014-09-11 |
WO2014138425A1 (en) | 2014-09-12 |
US9402913B2 (en) | 2016-08-02 |
WO2014138359A1 (en) | 2014-09-12 |
US20140256658A1 (en) | 2014-09-11 |
CA2899500A1 (en) | 2014-09-12 |
AU2014225637A1 (en) | 2015-09-03 |
WO2014138403A1 (en) | 2014-09-12 |
SG11201507241UA (en) | 2015-10-29 |
KR20150125663A (ko) | 2015-11-09 |
CL2015002210A1 (es) | 2016-01-22 |
TW201511758A (zh) | 2015-04-01 |
JP2016510754A (ja) | 2016-04-11 |
BR112015021388A2 (pt) | 2017-07-18 |
CN105025929A (zh) | 2015-11-04 |
AR095073A1 (es) | 2015-09-16 |
RU2015135145A (ru) | 2017-04-13 |
EP2964268A1 (en) | 2016-01-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR095072A1 (es) | Conjugados antibióticos | |
UY36075A (es) | Derivados de tubulisina | |
WO2017062271A3 (en) | Antibody drug conjugate for anti-inflammatory applications | |
PH12016501411B1 (en) | Bifunctional cytotoxic agents | |
BR112015027321A8 (pt) | Compostos e composições para modular a expressão de apolipoproteína(a) e seus usos | |
PE20150892A1 (es) | Anticuerpos anti-notch y conjugados de anticuerpo-farmaco | |
UY36186A (es) | Ácidos grasos novedosos y su uso en la conjugación con biomoléculas | |
DK3283521T3 (da) | Lægemiddelkonjugater, der omfatter antistoffer mod claudin 18.2 | |
MX2021010550A (es) | Conjugados de anticuerpo-farmaco hidrofilicos. | |
EA201690780A1 (ru) | Пегилированные лекарственные средства-линкеры для улучшенной фармакокинетики конъюгатов лиганд-лекарственное средство | |
EP3307749A4 (en) | HYDROPHILIC LINKER FOR CONJUGATION | |
EP3082797A4 (en) | Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof | |
EA201992456A3 (ru) | Самостабилизирующиеся линкерные конъюгаты | |
CL2012000092A1 (es) | Compuestos derivados de piridina y pirazina o una sal de los mismos, moduladores de proteina quinasa cdk9; composicion farmaceutica que los comprende, util para el tratamiento del cancer, hipotrofia cardiaca, vih y enfermedades inflamatorias. | |
NZ703581A (en) | Anti-cd70 antibody drug conjugates | |
BR112015021134A2 (pt) | conjugados de fármaco e anticorpo | |
WO2015067570A3 (en) | Pharmaceutical combinations comprising cd33 antibodies and de-methylating agents | |
BR112015011118A2 (pt) | conjugado; composição farmacêutica; e uso de um ou mais dos conjugados | |
MX2017008215A (es) | Conjugados de farmacos proteinas de union que comprenden derivados de antraciclina. | |
ECSP13013060A (es) | Composiciones de nucleasa terapéuticas y métodos | |
EP3086815A4 (en) | Sulfonamide-containing linkage systems for drug conjugates | |
CL2016000009A1 (es) | Tratamiento de rosacea papulopustular con ivermectina. | |
WO2015073575A3 (en) | Residualizing linkers and uses thereof | |
CY1121852T1 (el) | Μορφοποιησεις και μεθοδοι παρασκευης μορφοποιησεων για χρηση στον καθαρισμο του παχεος εντερου | |
TR201910866T4 (tr) | Kanser tedavisi için birleşik preparasyonlar. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |